In patients with cancer-related VTE, new guidelines recommend the use of LMWH (or UFH/fonda, but not warfarin) for treatment and prophylaxis, and vena cava filters for those who cannot be medically treated for VTE. Post operative prophylaxis should be continued for 4 weeks. Prophylaxis should be considered for patients with locally advanced or metastatic prostate or lung cancer on chemotherapy. For those with venous catheters, they should not be routinely given prophylaxis, but those with a thrombus should receive 3 months of treatment. The full guidelines can be found here (abstract).
Share This Post
Categories
Related Posts
I am coming up on my two year anniversary. Not my wedding anniversary (soon to be 15 years – thanks Maia!), but two years since I joined the ranks of the patients. It was two years ago this week that my day was interrupted by a page from my internist saying, “I don’t know how […]
As you can see, no glamour shots for this month’s post. I knew it would come at some point, and my first hospitalization related to my CLL came in a big way in mid-July. Given my interest in global health, it was only fitting that I managed to get sick while out of the […]
This large multicenter trial randomized patients with acute VTE to apixaban (10mg BID for 1 week, followed by 5mg BID for 6 months) versus conventional therapy (lovenox-warfarin). The primary outcome was similar between groups (symptomatic VTE or death related to VTE), but major and minor bleeding occurred significantly less often with apixaban. Apixaban is a […]
Leave A Comment